A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients

BMC Psychiatry

Volumn 7, Issue , 2007, Pages

  Mackin, Paul ^a   Bishop, David R ^a   Watkinson, Helen M O ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANTILIPEMIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; GABAPENTIN; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMOTRIGINE; LITHIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PIPOTIAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; TRIACYLGLYCEROL; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; UNINDEXED DRUG; VALPROIC ACID; ZUCLOPENTHIXOL;

ADULT; ANTHROPOMETRY; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; BODY MASS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMMUNITY LIVING; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; METABOLIC DISORDER; MOOD DISORDER; OBESITY; PATIENT MONITORING; PREVALENCE; PROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; UNITED KINGDOM; WAIST CIRCUMFERENCE; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; MONITORING; RISK;

ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MALE; METABOLIC DISEASES; MIDDLE AGED; MONITORING, PHYSIOLOGIC; OBESITY; PREVALENCE; PROSPECTIVE STUDIES; RISK;

EID: 34447336969     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-7-28     Document Type: Article

References (23)

1. Brown S Excess mortality of schizophrenia. A meta-analysis Br J Psychiatry 1997 171 502-508 9519087
2. Phelan M Stradins L Morrison S Physical health of people with severe mental illness BMJ 2001 322 7284 443-444 1119672 11222406 10.1136/ bmj.322.7284.443
3. Taylor D Young C Esop R Paton C Walwyn R Testing for diabetes in hospitalised patients prescribed antipsychotic drugs Br J Psychiatry 2004 185 152-156 10.1192/bjp.185.2.152 15286067
4. Mackin P Watkinson HM Young AH Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: A cross-sectional study Diabetologia 2005 48 2 215-221 10.1007/s00125-004-1641-y 15688206
5. Cohen D Stolk RP Grobbee DE Gispen-de Wied CC Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders Diabetes Care 2006 29 4 786-791 10.2337/diacare.29.04.06.dc05-1261 16567816
6. Nasrallah HA Meyer JM Goff DC McEvoy JP Davis SM Stroup TS Lieberman JA Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline Schizophr Res 2006 16884895
7. De Hert M van Winkel R Van Eyck D Hanssens L Wampers M Scheen A Peuskens J Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: A cross-sectional study Clin Pract Epidemol Ment Health 2006 2 14 1533826 16803620 10.1186/ 1745-0179-2-14
8. Consensus development conference on antipsychotic drugs and obesity and diabetes J Clin Psychiatry 2004 65 2 267-272 15003083
9. Barnett AH Mackin P Chaudhry I Farooqi A Gadsby R Heald A Hill J Millar H Peveler R Rees A Singh V Taylor D Vora J Jones P Minimising metabolic and cardiovascular risk in schizophrenia: Diabetes, obesity and dyslipidaemia J Psychopharmacol 2007 17446199
10. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care National Institute for Clinical Excellence 2002
11. Bipolar disorder: The Management of bipolar disorder in adults, children and adolescents, in primary and secondary care National Institute for Clinical Excellence 2006
12. Cohn TA Sernyak MJ Metabolic monitoring for patients treated with antipsychotic medications Canadian journal of psychiatry 2006 51 8 492-501
13. Lieberman JA Stroup TS McEvoy JP Swartz MS Rosenheck RA Perkins DO Keefe RS Davis SM Davis CE Lebowitz BD Severe J Hsiao JK Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 2005 353 12 1209-1223 10.1056/NEJMoa051688 16172203
14. De Hert M van Eyck D De Nayer A Metabolic abnormalities associated with second generation antipsychotics: Fact or fiction? Development of guidelines for screening and monitoring Int Clin Psychopharmacol 2006 21 Suppl 2 S11-5 10.1097/01.yic.0000201496.23259.85 16601508
15. Levy JC Matthews DR Hermans MP Correct homeostasis model assessment (HOMA) evaluation uses the computer program Diabetes Care 1998 21 12 2191-2192 10.2337/diacare.21.12.2191 9839117
16. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group Diabetes 1979 28 12 1039-1057 510803
17. SPSS SPSS for Windows, version 11 Chicago, IL, SPSS inc. 2001
18. Alberti KG Zimmet P Shaw J Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation Diabet Med 2006 23 5 469-480 10.1111/j.1464-5491.2006.01858.x 16681555
19. Ohlson LO Larsson B Svardsudd K Welin L Eriksson H Wilhelmsen L Bjorntorp P Tibblin G The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913 Diabetes 1985 34 10 1055-1058 10.2337/diabetes.34.10.1055 4043554
20. Rexrode KM Carey VJ Hennekens CH Walters EE Colditz GA Stampfer MJ Willett WC Manson JE Abdominal adiposity and coronary heart disease in women Jama 1998 280 21 1843-1848 10.1001/jama.280.21.1843 9846779
21. Brown S Inskip H Barraclough B Causes of the excess mortality of schizophrenia Br J Psychiatry 2000 177 212-217 10.1192/bjp.177.3.212 11040880
22. Mukherjee S Schnur DB Reddy R Family history of type 2 diabetes in schizophrenic patients Lancet 1989 1 8636 495 10.1016/ S0140-6736(89)91392-5 2563862
23. Gough SC O'Donovan M C Clustering of metabolic comorbidity in schizophrenia: A genetic contribution? J Psychopharmacol 2005 19 6 Suppl 47-55 10.1177/0269881105058380 16280337